📰 Nasdaq Regn News
Page 2 - Nasdaq Regn News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Regn. Real-time updates on events, politics, business and more.
April 23, 2024
MCF Advisors LLC grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 50.0% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 36 shares of the biopharmaceutical company’s stock after purchasing an additional 12 shares during the period. MCF Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $32,000 as […]
April 23, 2024
MCF Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 50.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 36 shares of the biopharmaceutical company’s stock after acquiring an additional 12 shares during the period. […]
April 23, 2024
Linden Thomas Advisory Services LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,607 shares of the biopharmaceutical company’s stock after purchasing an additional 136 shares […]
April 21, 2024
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target raised by UBS Group from $1,090.00 to $1,099.00 in a report released on Wednesday, Benzinga reports. UBS Group currently has a buy rating on the biopharmaceutical company’s stock. REGN has been the topic of a number of other reports. Royal Bank of Canada reaffirmed an […]
April 9, 2024
Tobam lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 13.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,564 shares of the biopharmaceutical company’s stock after selling 730 shares during the period. Tobam’s holdings in Regeneron Pharmaceuticals […]
April 9, 2024
Stiles Financial Services Inc increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 12.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,033 shares of the biopharmaceutical company’s stock after purchasing an additional 334 shares during the […]
April 9, 2024
Stiles Financial Services Inc increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 12.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,033 shares of the biopharmaceutical company’s stock after purchasing an additional 334 shares during the […]
April 8, 2024
Bleakley Financial Group LLC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 10.6% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 8,977 shares of the biopharmaceutical company’s stock after buying an additional 860 shares during the period. Bleakley Financial Group LLC’s holdings in Regeneron Pharmaceuticals were worth […]
April 8, 2024
Valley National Advisers Inc. increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 1.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,394 shares of the biopharmaceutical company’s stock after acquiring an additional 24 shares during the period. Valley […]
April 8, 2024
Valley National Advisers Inc. raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 1.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,394 shares of the biopharmaceutical company’s stock after purchasing an additional 24 shares during the quarter. Valley […]